AXSM
Axsome Therapeutics Inc
$206.68-0.80%
Setup
Near pivot
Buy Zone
$210.59-$221.12
Sector
Biotechnology
Industry
Biotechnology
49
Recommendation
Avoid
Avoid
Too many CANSLIM criteria failing.
AXSM chart
Loading chart…
ADX
Developing24.5Long Term
Up ↑Intermediate Term
Up ↑Short Term
Range →Overall Quality49
RS Rating
84
relative strength
Fundamentals
42
Weak fund-Q
Volume Demand
45
-48% vs avg
Technical Setup
38
3/8 checks
Industry/Theme
91
Biotechnology
Trade Plan
Avoid
Entry
$210.59
Entry Zone
$210.59-$221.12
Stop / Risk
$193.74
RS Rating
84
Volume confirmed
No
Targets
$252.71 / $263.24
Breakout · IBD Setup
4 ✓ 4 ✗
Entry $210.59–$221.12Stop $193.74Target $252.71 / $263.24
Market regimeUptrend
Quality49
RS Rating84
Above 50-MA-7.63%
Above 200-MA+6.14%
VolumeWeak
In Buy ZoneNo
Not extendedOK
Invalidation · Close below stop
How this came together
49
MarketUptrend
SetupNear pivot
ConfidenceExperimental · not backtested
Fund-Q42 · Weak
StatusAvoid
Stock Data
52-Week Range113 – 260
Price % Chg YTD13.16%
Price % Chg 4wk-1.64%
50-Day Avg Vol0.8 Mil
P/E Ratio—
Market Cap$11B
SectorHealthcare
IndustryBiotechnology
Company Fundamentals
EPS % Chg (Qtr)-2.09%
Sales % Chg (Qtr)45.54%
EPS Growth 5y-5.89%
Sales Growth 5y—
Annual ROE-245.1%
Gross Margin91.96%
Operating Margin-23.55%
Net Margin-24.68%
Debt / Equity2.70
Setup levels
Current price
$206.68
Pivot
$210.59
Distance to buy
-20.6%
52-week range
112.9-260.2
Trigger evidence
No active trigger evidence available.
Pattern levels: pivot 210.59
Financial health checks
1/5
Return on equity above 15%
ROE -245.1%
Net margin above 10%
Net margin -24.68%
EPS growing quarter on quarter
EPS q/q -2.09%
Sales growing quarter on quarter
Sales q/q 45.54%
Debt to equity below 1.0
D/E 2.70
Key metrics
Finviz snapshot · value vs. sector median (≥5 peers)
Annual ROE-245.1%
vs sector -267.2%
Net margin-24.68%
vs sector -41.7%
Gross margin91.96%
vs sector +25.3%
EPS growth q/q-2.09%
vs sector -10.1%
Sales growth q/q45.54%
vs sector +27.0%
Debt / equity2.70
vs sector +2.06
Business quality
42
GradeWeak
EPS rating25
P/E—
Market cap$11B
IndustryBiotechnology
Technical checks
Über 50-MA
Fail
Über 200-MA
Pass
RS-Linie auf neuem Hoch
Fail
Volumen bestätigt
Fail
In Kaufzone
Fail
Nicht überextended
Pass
Über 21-EMA
Fail
Volumen gesund
Pass
IBD / source mentions
No recent IBD mention found for this ticker.
Signal history
Added to list
2026-09-04
Trigger date
—
Days on list
3
Data sources: internal CANSLIM engine · Finviz snapshot · TradingView chart. Not investment advice.